{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:04:35Z","timestamp":1780085075596,"version":"3.54.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Standard initial therapy with intensive glucocorticoids requires further optimization due to high relapse rates and unsatisfying long-term outcomes in patients with primary immune thrombocytopenia (ITP). Caffeic acid (CA) has been reported to increase platelet counts in thrombocytopenia. This study investigated the efficacy and safety of CA tablets plus high-dose dexamethasone (HD-DXM) as a novel initial treatment for adults with newly diagnosed ITP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This multicenter, double-blind, randomized, placebo-controlled trial was conducted from July 1, 2015 to February 28, 2022 in fourteen tertiary medical hospitals in China. Eligible patients aged \u226518 years with newly diagnosed, treatment-na\u00efve primary ITP who had a baseline platelet count of &lt;30 \u00d7 10<jats:sup>9<\/jats:sup>\/L were enrolled during routine outpatient visits. Participants were randomly assigned in a 1:1 ratio to receive either CA tablets (0.3 g three times daily for 12 weeks) plus HD-DXM (40 mg\/day for four days, repeated with a 10-day interval) or placebo plus HD-DXM. The primary endpoint was a 24-week sustained response (SR), defined as the maintenance of a platelet count higher than 30 \u00d7 10<jats:sup>9<\/jats:sup>\/L, at least doubling of the baseline platelet count, and an absence of bleeding. The Chi-squared test and Kaplan\u2013Meier method were used to compare the 24-week SR and duration of response (DOR) between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The intention to treat analysis included 214 patients who received at least one-dose of allocated treatments (median [Q<jats:sub>1<\/jats:sub>\u2013Q<jats:sub>3<\/jats:sub>] age, 45 [32\u201355] years; 154 females [72.0%]). At week 24, 56.5% (61\/108) of participants in the CA plus HD-DXM group achieved SR, which was significantly higher than 29.2% (31\/106) of those in the placebo plus HD-DXM group (odds ratio [OR] 3.14; 95% confidence interval [CI] 1.78\u20135.53; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.0001). Adding CA to HD-DXM resulted in a longer DOR than the placebo (hazard ratio 0.50; 95% CI 0.34\u20130.74; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.00028). The most commonly observed adverse events (AEs) in both groups were gastrointestinal symptoms, anxiety or mood disorders, and fatigue, without statistically significant differences. No grade 4 or worse AEs or death occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study confirms CA tablets plus HD-DXM as a well-tolerated, cost-effective, and optimized initial therapy for patient with newly-diagnosed ITP to conveniently maintain platelet counts and avoid early relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov. NCT02556814.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003783","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T03:00:25Z","timestamp":1755918025000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Caffeic acid tablets plus high-dose dexamethasone versus placebo plus high-dose dexamethasone in patients with newly diagnosed immune thrombocytopenia: A multicenter, double-blind, randomized, controlled, phase 2 trial"],"prefix":"10.1097","author":[{"given":"Ruting","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunliang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jining First People\u2019s Hospital, Jining, Shandong 272011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiwu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Liaocheng People\u2019s Hospital, Liaocheng, Shandong 252000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong 253014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, Shandong 264001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Weihai Municipal Hospital, Weihai, Shandong 264200, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zibo Central Hospital, Zibo, Shandong 250036, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, ShengLi Oilfield Central Hospital, Dongying, Shandong 257099, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"R1-20250823","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"R2-20250823","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R3-20250823","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R4-20250823","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3760\/cma.j.issn.0366-6999.20123000","article-title":"Chinese contribution to immune thrombocytopenia: The pathogenesis-oriented treatment","volume":"126","author":"Qin","year":"2013","journal-title":"Chin Med J"},{"key":"R5-20250823","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"R6-20250823","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: A systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"R7-20250823","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/09537104.2019.1572875","article-title":"First line treatment of adult patients with primary immune thrombocytopenia: A real-world study","volume":"31","author":"Wang","year":"2020","journal-title":"Platelets"},{"key":"R8-20250823","doi-asserted-by":"crossref","first-page":"101777","DOI":"10.1016\/j.eclinm.2022.101777","article-title":"Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis","volume":"56","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R9-20250823","doi-asserted-by":"crossref","first-page":"e35353","DOI":"10.1097\/MD.0000000000035353","article-title":"Efficacy and safety of caffeic acid tablets in the treatment of thrombocytopenia: A systematic review and meta-analysis","volume":"102","author":"Yu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R10-20250823","first-page":"103","article-title":"A multicenter clinical trial of caffeic acid tablet in treatment of 103 primary immune thrombocytopenia patients (in Chinese)","volume":"36","author":"Qin","year":"2015","journal-title":"Chin J Hematol"},{"key":"R11-20250823","first-page":"817","article-title":"A randomized, double-blind multicentre clinical trial comparing the efficacy and safety of Caffeic acid for the treatment of immune thrombocytopenia in China (in Chinese)","volume":"37","year":"2017","journal-title":"Chin J Pract Intern Med"},{"key":"R12-20250823","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2010-07-295477","article-title":"High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia","volume":"117","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"R13-20250823","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/jth.13767","article-title":"High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia","volume":"15","author":"Feng","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R14-20250823","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2015-10-674531","article-title":"High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia","volume":"127","author":"Hou","year":"2016","journal-title":"Blood"},{"key":"R15-20250823","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41423-022-00859-0","article-title":"Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia","volume":"19","author":"Hou","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"R16-20250823","doi-asserted-by":"crossref","first-page":"156471","DOI":"10.1016\/j.cyto.2023.156471","article-title":"The inhibition effect of caffeic acid on NOX\/ROS-dependent macrophages M1-like polarization contributes to relieve the LPS-induced mice mastitis","volume":"174","author":"Yu","year":"2024","journal-title":"Cytokine"},{"key":"R17-20250823","doi-asserted-by":"crossref","first-page":"104364","DOI":"10.1016\/j.cellimm.2021.104364","article-title":"Blockade of TLRs-triggered macrophage activation by caffeic acid exerted protective effects on experimental ulcerative colitis","volume":"365","author":"Xiang","year":"2021","journal-title":"Cell Immunol"},{"key":"R18-20250823","doi-asserted-by":"crossref","first-page":"102349","DOI":"10.1016\/j.rpth.2024.102349","article-title":"Platelet RNA sequencing reveals profile of caffeic acid affecting hemostasis in mice","volume":"8","author":"Deng","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"R19-20250823","first-page":"876","article-title":"Clinical observation of caffeic acid in the treatment of thrombocytopenia (CIT) caused by cancer chemotherapy [in Chinese]","volume":"44","author":"Shen","year":"2017","journal-title":"Chin J Clin Oncol"},{"key":"R20-20250823","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.fct.2018.10.040","article-title":"Reproductive and developmental toxicity study of caffeic acid in mice","volume":"123","author":"Liu","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"R21-20250823","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/ajh.25989","article-title":"High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial","volume":"95","author":"Yu","year":"2020","journal-title":"Am J Hematol"},{"key":"R22-20250823","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"key":"R23-20250823","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(21)00030-2","article-title":"Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"8","author":"Sun","year":"2021","journal-title":"Lancet Haematol"},{"key":"R24-20250823","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R25-20250823","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R26-20250823","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.clinthera.2007.05.005","article-title":"A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial","volume":"29","author":"Mathias","year":"2007","journal-title":"Clin Ther"},{"key":"R27-20250823","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"R28-20250823","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N Engl J Med"},{"key":"R29-20250823","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000003306","article-title":"Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed\/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells","author":"Chen","year":"2024","journal-title":"Chin Med J"},{"key":"R30-20250823","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"R31-20250823","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"R32-20250823","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"R33-20250823","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000362529","article-title":"Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia","volume":"133","author":"Din","year":"2015","journal-title":"Acta Haematol"},{"key":"R34-20250823","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"R35-20250823","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.22211","article-title":"Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIb\u03b1 antibodies","volume":"87","author":"Zeng","year":"2012","journal-title":"Am J Hematol"},{"key":"R36-20250823","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"R37-20250823","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-017-0413-3","article-title":"Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia","volume":"10","author":"Tao","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R38-20250823","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2018.1548930","article-title":"Health-related quality of life in adult primary immune thrombocytopenia","volume":"11","author":"Sest\u00f8l","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"R39-20250823","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"R40-20250823","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"key":"R41-20250823","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"R42-20250823","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.15034","article-title":"Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3\/NF-\u03baB\/SMAD pathway in patients with immune thrombocytopenia","volume":"180","author":"He","year":"2018","journal-title":"Br J Haematol"},{"key":"R43-20250823","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.fct.2011.10.043","article-title":"Caffeic acid attenuates 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced NF-\u03baB and COX-2 expression in mouse skin: abrogation of oxidative stress, inflammatory responses and proinflammatory cytokine production","volume":"50","author":"Khan","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"R44-20250823","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.intimp.2017.04.025","article-title":"Caffeic acid alleviates inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes by inhibiting phosphorylation of I\u03baB kinase \u03b1\/\u03b2 and I\u03baB\u03b1","volume":"48","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"R45-20250823","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1182\/blood-2011-02-338897","article-title":"Oxidative stress may cause ITP","volume":"117","author":"Imbach","year":"2011","journal-title":"Blood"},{"key":"R46-20250823","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2010-09-304931","article-title":"The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP","volume":"117","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"R47-20250823","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jfda.2016.05.003","article-title":"Inhibitory mechanism against oxidative stress of caffeic acid","volume":"24","author":"Khan","year":"2016","journal-title":"J Food Drug Anal"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T03:00:33Z","timestamp":1755918033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003783","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-04-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}